GT Biopharma, Inc. (GTBP) stock
GTBPNasdaqPharmaceutical PreparationsFiscal year ends December 31
$3.43+0.25 (+7.86%)
Close on Nov 18, 2026Market cap $154.73MP/E –Yield –
GT Biopharma operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
GT Biopharma's operating cash flow for the twelve months ending Jun 30, 2026 was -$14.43M. For fiscal 2025 it was -$12.91M. The highest annual figure on record is -$442.00K in fiscal 2013.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$12.91M | – |
| FY2024 | Dec 31, 2024 | -$12.90M | – |
| FY2023 | Dec 31, 2023 | -$8.85M | – |
| FY2022 | Dec 31, 2022 | -$15.22M | – |
| FY2021 | Dec 31, 2021 | -$15.61M | – |
| FY2020 | Dec 31, 2020 | -$7.26M | – |
| FY2019 | Dec 31, 2019 | -$3.66M | – |
| FY2018 | Dec 31, 2018 | -$10.68M | – |
| FY2017 | Dec 31, 2017 | -$5.43M | – |
| FY2016 | Dec 31, 2016 | -$1.93M | – |
| FY2015 | Dec 31, 2015 | -$4.66M | – |
| FY2014 | Dec 31, 2014 | -$1.75M | – |
| FY2013 | Dec 31, 2013 | -$442.00K | – |
| FY2012 | Dec 31, 2012 | -$987.00K | – |
| FY2011 | Dec 31, 2011 | -$963.00K | – |
| FY2010 | Dec 31, 2010 | -$1.54M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$4.26M | – |
| Q1 FY2026 | Mar 31, 2026 | -$2.47M | – |
| Q4 FY2025 | Dec 31, 2025 | -$4.02M | – |
| Q3 FY2025 | Sep 30, 2025 | -$3.68M | – |
| Q2 FY2025 | Jun 30, 2025 | -$3.01M | – |
| Q1 FY2025 | Mar 31, 2025 | -$2.20M | – |
| Q4 FY2024 | Dec 31, 2024 | -$2.47M | – |
| Q3 FY2024 | Sep 30, 2024 | -$2.74M | – |
| Q2 FY2024 | Jun 30, 2024 | -$3.54M | – |
| Q1 FY2024 | Mar 31, 2024 | -$4.16M | – |
| Q4 FY2023 | Dec 31, 2023 | -$2.05M | – |
| Q3 FY2023 | Sep 30, 2023 | -$1.96M | – |
| Q2 FY2023 | Jun 30, 2023 | -$1.94M | – |
| Q1 FY2023 | Mar 31, 2023 | -$2.91M | – |
| Q4 FY2022 | Dec 31, 2022 | -$4.30M | – |
| Q3 FY2022 | Sep 30, 2022 | -$2.92M | – |
| Q2 FY2022 | Jun 30, 2022 | -$2.79M | – |
| Q1 FY2022 | Mar 31, 2022 | -$5.22M | – |
| Q4 FY2021 | Dec 31, 2021 | -$3.71M | – |
| Q3 FY2021 | Sep 30, 2021 | -$3.93M | – |
| Q2 FY2021 | Jun 30, 2021 | -$4.29M | – |
| Q1 FY2021 | Mar 31, 2021 | -$3.68M | – |
| Q4 FY2020 | Dec 31, 2020 | -$1.93M | – |
| Q3 FY2020 | Sep 30, 2020 | -$1.70M | – |
| Q2 FY2020 | Jun 30, 2020 | -$3.41M | – |
| Q1 FY2020 | Mar 31, 2020 | -$223.00K | – |
| Q4 FY2019 | Dec 31, 2019 | -$485.00K | – |
| Q3 FY2019 | Sep 30, 2019 | -$1.13M | – |
| Q2 FY2019 | Jun 30, 2019 | -$1.09M | – |
| Q1 FY2019 | Mar 31, 2019 | -$961.00K | – |
| Q4 FY2018 | Dec 31, 2018 | -$1.24M | – |
| Q3 FY2018 | Sep 30, 2018 | -$3.43M | – |
| Q2 FY2018 | Jun 30, 2018 | -$1.77M | – |
| Q1 FY2018 | Mar 31, 2018 | -$4.23M | – |
| Q4 FY2017 | Dec 31, 2017 | -$2.15M | – |
| Q3 FY2017 | Sep 30, 2017 | -$2.24M | – |
| Q2 FY2017 | Jun 30, 2017 | -$391.00K | – |
| Q1 FY2017 | Mar 31, 2017 | -$650.00K | – |
| Q4 FY2016 | Dec 31, 2016 | -$135.00K | – |
| Q3 FY2016 | Sep 30, 2016 | -$563.00K | – |
See a number that looks wrong?